Exonics Therapeutics nabs $40 mln Series A
Cambridge, Massachusetts-based Exonics Therapeutics Inc, a biotech company focused on developing gene editing technologies to Duchenne muscular dystrophy and other neuromuscular diseases, has raised $40 million in Series A financing. The backer was The Column Group. In addition to the funding, TCG’s Dr. David Goeddel, a managing partner, and Dr. JJ Kang, a principal, will join Exonics' board of directors.
9 November 2017•1 min read
